212 related articles for article (PubMed ID: 26671515)
1. Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer.
Di Caro S; Cheung WH; Fini L; Keane MG; Theis B; Haidry R; Di Renzo L; De Lorenzo A; Lovat L; Batterham RL; Banks M
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):251-60. PubMed ID: 26671515
[TBL] [Abstract][Full Text] [Related]
2. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.
Duggan C; Onstad L; Hardikar S; Blount PL; Reid BJ; Vaughan TL
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):934-43. PubMed ID: 23466711
[TBL] [Abstract][Full Text] [Related]
3. The Role of Visceral Adiposity Index Levels in Predicting the Presence of Metabolic Syndrome and Insulin Resistance in Overweight and Obese Patients.
Pekgor S; Duran C; Berberoglu U; Eryilmaz MA
Metab Syndr Relat Disord; 2019 Jun; 17(5):296-302. PubMed ID: 30932744
[No Abstract] [Full Text] [Related]
4. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
[TBL] [Abstract][Full Text] [Related]
5. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
6. Relationship of Insulin Resistance to Prevalence and Progression of Coronary Artery Calcification Beyond Metabolic Syndrome Components: Shiga Epidemiological Study of Subclinical Atherosclerosis.
Yamazoe M; Hisamatsu T; Miura K; Kadowaki S; Zaid M; Kadota A; Torii S; Miyazawa I; Fujiyoshi A; Arima H; Sekikawa A; Maegawa H; Horie M; Ueshima H;
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1703-8. PubMed ID: 27283744
[TBL] [Abstract][Full Text] [Related]
7. Serum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett's esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD.
Mokrowiecka A; Daniel P; Jasinska A; Pietruczuk M; Pawlowski M; Szczesniak P; Orszulak-Michalak D; Malecka-Panas E
Hepatogastroenterology; 2012; 59(120):2395-9. PubMed ID: 22944288
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium.
Gopal DV; Lieberman DA; Magaret N; Fennerty MB; Sampliner RE; Garewal HS; Falk GW; Faigel DO
Dig Dis Sci; 2003 Aug; 48(8):1537-41. PubMed ID: 12924649
[TBL] [Abstract][Full Text] [Related]
10. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.
Gatenby P; Bhattacharjee S; Wall C; Caygill C; Watson A
World J Gastroenterol; 2016 Dec; 22(48):10592-10600. PubMed ID: 28082811
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
14. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
15. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
16. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
Durmus U; Duran C; Ecirli S
J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
[TBL] [Abstract][Full Text] [Related]
17. Barrett's esophagus and cancer risk: a more realistic estimate.
Rajendra S; Sharma P
Semin Thorac Cardiovasc Surg; 2011; 23(4):261-2. PubMed ID: 22443641
[TBL] [Abstract][Full Text] [Related]
18. Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.
Lau CH; Muniandy S
Cardiovasc Diabetol; 2011 Jan; 10():8. PubMed ID: 21251282
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
20. Is Obesity Associated with Barrett's Esophagus and Esophageal Adenocarcinoma?
Lynch KL
Gastroenterol Clin North Am; 2016 Dec; 45(4):615-624. PubMed ID: 27837776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
